Platelet MHC class I mediates CD8+ T-cell suppression during sepsis.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
05 08 2021
Historique:
received: 01 09 2020
accepted: 13 01 2021
pubmed: 26 4 2021
medline: 15 12 2021
entrez: 25 4 2021
Statut: ppublish

Résumé

Circulating platelets interact with leukocytes to modulate host immune and thrombotic responses. In sepsis, platelet-leukocyte interactions are increased and have been associated with adverse clinical events, including increased platelet-T-cell interactions. Sepsis is associated with reduced CD8+ T-cell numbers and functional responses, but whether platelets regulate CD8+ T-cell responses during sepsis remains unknown. In our current study, we systemically evaluated platelet antigen internalization and presentation through major histocompatibility complex class I (MHC-I) and their effects on antigen-specific CD8+ T cells in sepsis in vivo and ex vivo. We discovered that both human and murine platelets internalize and proteolyze exogenous antigens, generating peptides that are loaded onto MHC-I. The expression of platelet MHC-I, but not platelet MHC-II, is significantly increased in human and murine platelets during sepsis and in human megakaryocytes stimulated with agonists generated systemically during sepsis (eg, interferon-γ and lipopolysaccharide). Upregulation of platelet MHC-I during sepsis increases antigen cross-presentation and interactions with CD8+ T cells in an antigen-specific manner. Using a platelet lineage-specific MHC-I-deficient mouse strain (B2Mf/f-Pf4Cre), we demonstrate that platelet MHC-I regulates antigen-specific CD8+ T-cell proliferation in vitro, as well as the number and functional responses of CD8+ T cells in vivo, during sepsis. Loss of platelet MHC-I reduces sepsis-associated mortality in mice in an antigen-specific setting. These data identify a new mechanism by which platelets, through MHC-I, process and cross-present antigens, engage antigen-specific CD8+ T cells, and regulate CD8+ T-cell numbers, functional responses, and outcomes during sepsis.

Identifiants

pubmed: 33895821
pii: S0006-4971(21)00936-8
doi: 10.1182/blood.2020008958
pmc: PMC8343546
doi:

Substances chimiques

Histocompatibility Antigens Class I 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

401-416

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002538
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL145237
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130541
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL142804
Pays : United States
Organisme : CSRD VA
ID : I01 CX001696
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144957
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL155856
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 by The American Society of Hematology.

Auteurs

Li Guo (L)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Sikui Shen (S)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
West China Hospital, Sichuan University, Chengdu, China.

Jesse W Rowley (JW)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Pulmonary and Critical Care Division, Department of Medicine, School of Medicine, University of Utah, Salt Lake City, UT.

Neal D Tolley (ND)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Wenwen Jia (W)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.

Bhanu Kanth Manne (BK)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Kyra N McComas (KN)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Ben Bolingbroke (B)

Department of Biomedical Engineering, University of Utah, Salt Lake City, UT.

Yasuhiro Kosaka (Y)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Krystin Krauel (K)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.

Frederik Denorme (F)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Shancy P Jacob (SP)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.

Alicia S Eustes (AS)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Internal Medicine, University of Iowa, Iowa City, IA.

Robert A Campbell (RA)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Division of General Internal Medicine, Department of Medicine, School of Medicine, and.

Elizabeth A Middleton (EA)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Pulmonary and Critical Care Division, Department of Medicine, School of Medicine, University of Utah, Salt Lake City, UT.

Xiao He (X)

Department of Pathology, University of Utah, Salt Lake City, UT.

Samuel M Brown (SM)

Pulmonary and Critical Care Division, Department of Medicine, School of Medicine, University of Utah, Salt Lake City, UT.
Center for Humanizing Critical Care, Intermountain Healthcare, Murray, UT.
Pulmonary and Critical Care Division, Department of Medicine, Intermountain Medical Center, Murray, UT.

Craig N Morrell (CN)

Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, NY; and.

Andrew S Weyrich (AS)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Pulmonary and Critical Care Division, Department of Medicine, School of Medicine, University of Utah, Salt Lake City, UT.

Matthew T Rondina (MT)

Molecular Medicine Program, University of Utah, Salt Lake City, UT.
Division of General Internal Medicine, Department of Medicine, School of Medicine, and.
Department of Pathology, University of Utah, Salt Lake City, UT.
Department of Internal Medicine, George E. Wahlen VA Medical Center and Geriatric Research Education Clinical Center (GRECC), Salt Lake City, UT.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH